The Modern Pharmacist
Author: Otto E. Bruder
Publisher:
Published: 1910
Total Pages: 344
ISBN-13:
DOWNLOAD EBOOKRead and Download eBook Full
Author: Otto E. Bruder
Publisher:
Published: 1910
Total Pages: 344
ISBN-13:
DOWNLOAD EBOOKAuthor:
Publisher:
Published: 1975
Total Pages: 28
ISBN-13:
DOWNLOAD EBOOKAuthor: Mehmet Gunduz
Publisher: BoD – Books on Demand
Published: 2015-03-25
Total Pages: 236
ISBN-13: 9535120301
DOWNLOAD EBOOKCancer is one of the leading causes of death in most countries and its consequences result in huge economic, social and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause of cancer death among females. In this book, we discussed gene expression and DNA abnormalities including methylation in breast cancer. A recent important topic, roles of miRNAs and their potential use in cancer therapy have been discussed in this cancer type as well. Bioinformatics is very important part of recent human genome developments and data mining and thus this topic has also been added for the readers. It is hoped that this book will contribute to development of novel diagnostic as well as therapeutic approaches, which lead to cure of breast cancer.
Author: James Leong
Publisher: Adis
Published: 2016-10-13
Total Pages: 0
ISBN-13: 9783319367675
DOWNLOAD EBOOKThis book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox. Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured, systematic, standardized approach. Examining the evaluation of such an approach by several mature regulatory authorities ensures that the reader gains a unique insight into the ongoing debate in this area. The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Rather than provide a comprehensive snap-shot of this constantly changing environment, this book evaluates selected current approaches to benefit-risk assessment. The strengths and weaknesses of publicly available documents in communicating benefit-risk decisions to stakeholders are reviewed and these evaluations are used to inform development of a prospective framework that could be used to harmonise procedures globally.
Author: United States. Regulatory Council
Publisher:
Published: 1980
Total Pages: 40
ISBN-13:
DOWNLOAD EBOOK